Home › Funds › Invenomic Capital Management LP › GEHC
Invenomic Capital Management LP position in GEHC
GE HEALTHCARE TECHNOLOGIES I · Health Care
Invenomic Capital Management LP reported holding 579,705 shares of GEHC (GE HEALTHCARE TECHNOLOGIES I) in its Q3 2026 13F filing — a position valued at US$37.9M, representing 1.87% of its reported portfolio and ranking #14 among its reported holdings. Invenomic Capital Management LP has disclosed GEHC holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Invenomic Capital Management LP's GEHC position evolved
Invenomic Capital Management LP first disclosed a stake in GEHC in Q2 2025 at 96,697 shares (US$7.2M). The position peaked in Q3 2026 at 579,705 shares, worth US$37.9M. Across 3 filings, Invenomic Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 579,705 shares valued at US$37.9M — an increase of 346,670 shares quarter over quarter.. Notable position changes include a 149% increase in Q3 2026 (shares rose 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 96.70K | $7.16M | New |
| Q2 2026 | 233.03K | $14.92M | New |
| Q3 2026 | 579.71K | $37.90M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GEHC and 13F data
GEHC (GE HEALTHCARE TECHNOLOGIES I) is a Health Care company. 25 other funds we track also report a position in GEHC — the largest reported positions include DODGE & COX (US$3.16B), Dodge & Cox (US$2.42B), Harris Associates (Oakmark) (US$981.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GEHC
- DODGE & COX 48.30M sh · $3.16B · Q3 2026
- Dodge & Cox 37.86M sh · $2.42B · Q2 2026
- Harris Associates (Oakmark) 15.33M sh · $981.25M · Q2 2026
- HARRIS ASSOCIATES L P 14.85M sh · $970.50M · Q3 2026
- BARROW HANLEY MEWHINNEY & STRAUSS LLC 13.77M sh · $900.14M · Q3 2026
- HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 13.34M sh · $872.20M · Q3 2026
- TRIAN FUND MANAGEMENT, L.P. 3.09M sh · $201.69M · Q3 2026
More on Invenomic Capital Management LP
FAQ
How long has Invenomic Capital Management LP held GEHC?
Invenomic Capital Management LP has disclosed GEHC holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
What is Invenomic Capital Management LP's current position in GEHC?
As of Q3 2026, Invenomic Capital Management LP holds 579.71K shares of GEHC (GE HEALTHCARE TECHNOLOGIES I), valued at $37.90M, representing 1.87% of its reported portfolio and ranking #14.
Has Invenomic Capital Management LP been buying or selling GEHC?
In the latest 13F filing (Q3 2026), Invenomic Capital Management LP increased its position in GEHC. The position peaked in Q3 2026 at 579.71K shares.
Which other funds hold GEHC?
Other major institutional holders of GEHC include DODGE & COX, Dodge & Cox, Harris Associates (Oakmark), among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.